Status:
COMPLETED
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Arthritis, Psoriatic
Arthritis, Rheumatoid
Eligibility:
All Genders
4+ years
Brief Summary
The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain
Eligibility Criteria
Inclusion
- RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate
- Children from 4 to 17 years old with JIA polyarticular
Exclusion
- Clinically significant abnormal screening lab values
- Patients who are planning to undergo elective surgery during the study period.
- Other current autoimmune connective tissue diseases
Key Trial Info
Start Date :
April 1 2003
Trial Type :
OBSERVATIONAL
End Date :
April 1 2006
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00195377
Start Date
April 1 2003
End Date
April 1 2006
Last Update
June 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Madrid, Madrid, Spain, 28007